טוען...
Abciximab-induced delayed profound thrombocytopaenia
Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy. We present a case of a young woman who initially received abciximab infusion for undergoing percutaneous coronary inte...
שמור ב:
| הוצא לאור ב: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMJ Publishing Group
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5534833/ https://ncbi.nlm.nih.gov/pubmed/28576909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-219379 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|